Open Access
Article
Acquired endocrine resistance in breast cancer: implications for tumour metastasis
Edd Hayes1,Robert I Nicholson1,Stephen Hiscox1
1
Welsh School of Pharmacy, Redwood Building, Cardiff University, Cardiff, UK
DOI: 10.2741/3723 Volume 16 Issue 3, pp.838-848
Published: 01 January 2011
(This article belongs to the Special Issue Bone metastasis, the molecular, cellular and clinical prospects)
Abstract

Endocrine therapy is the treatment of choice in hormone receptor-positive breast cancer. However, the effectiveness of these agents is limited by the development of drug resistance, ultimately leading to disease progression and patient mortality. Whilst pre-clinical cell models of acquired endocrine resistance have demonstrated a role for altered growth factor signalling in the development of an endocrine insensitive phenotype, it is becoming apparent that acquisition of endocrine resistance in breast cancer is also accompanied by the development of an adverse cellular phenotype, with resistant cells exhibiting altered adhesive interactions, enhanced migratory and invasive behaviour, and a capacity to induce angiogenic responses in endothelium. Since invasion and metastasis of cancer cells is a major cause of mortality in breast cancer patients, elucidation of molecular mechanisms underlying the adverse cellular features that accompany acquired endocrine resistance and their subsequent targeting may provide a means of limiting the progression of such tumours in vivo.

Share and Cite
Edd Hayes, Robert I Nicholson, Stephen Hiscox. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Frontiers in Bioscience-Landmark. 2011. 16(3); 838-848.